June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Final Level of Myopia versus Age of Onset: Effect of Race and Age at Final Refraction
Author Affiliations & Notes
  • Mark A Bullimore
    College of Optometry, University of Houston, Houston, Texas, United States
  • Noel A Brennan
    Johnson and Johnson Vision, Jacksonville, Florida, United States
  • Footnotes
    Commercial Relationships   Mark Bullimore Alcon Research, Code C (Consultant/Contractor), Coopervision, Code C (Consultant/Contractor), Essilor, Code C (Consultant/Contractor), Eyenovia, Code C (Consultant/Contractor), Genentech, Code C (Consultant/Contractor), Johnson & Johnson Vision, Code C (Consultant/Contractor), Novartis, Code C (Consultant/Contractor), Vyluma, Code C (Consultant/Contractor); Noel Brennan Johnson & Johnson Vision, Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4244. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mark A Bullimore, Noel A Brennan; Final Level of Myopia versus Age of Onset: Effect of Race and Age at Final Refraction. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4244.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Myopia severity has a profound impact on visual impairment in later life. A patient’s final level of myopia may be lowered by myopia control, but also by delaying onset. Here we evaluate the influence of age of onset on the final recorded level of myopia.

Methods : Data were extracted from the following reports:
● two prospective cohort studies of myopia progression in East Asia where final recorded level of myopia is presented as a function of age of onset (Chua et al., 2016; Hu et al., 2020)
● two retrospective studies of myopia progression in India and the Netherlands (Verkicharla et al., 2004; Polling et al., 2021)
● two cross-sectional studies in Argentina and the UK (Iribarren et al., 2004; Williams et al., 2013).
For the above, age of onset was based on self-report of age at first spectacle prescription and the midpoint was used for all age ranges.
A seventh set of data comprised Finnish subjects originally recruited for a clinical trial and followed into adulthood (Parssinen et al., 2019). Subjects were divided into five groups according to age at recruitment which was used as a surrogate for age of onset.

Results : Figure 1 shows the final recorded level of myopia as a function of age of onset for the seven studies. Figure 1A shows data for the two East Asian studies. The myopia level is different because the reference ages are 11 and 17 years. The slopes are 0.97 and 0.68 D/year, meaning that each year later age of onset is associated with 0.97 or 0.68 D less myopia at the final refraction. Figure 1B shows data for the five non-East Asian studies. For four studies the slopes are substantially flatter, with slopes between 0.23 and 0.35 D/year. In contrast, the slope for the Finnish study was 0.87 D. Among subjects of European descent, increasing age of final refraction tended to be associated with higher levels of myopia.

Conclusions : Among East Asians, delaying onset of myopia by just one year has potential to lower the final level myopia by 0.75 D or more—equivalent to multiple years of myopia control with existing modalities. The benefit is lower, but meaningful, among non-East Asians. The trend linking age of final refraction with final myopia level suggests ongoing adult progression.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Final recorded level of myopia as a function of age of onset. A: East Asian studies. B: Non-East Asian studies

Final recorded level of myopia as a function of age of onset. A: East Asian studies. B: Non-East Asian studies

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×